Bio Techne (TECH) Fell on Negative Funding Environment
Mairs & Power, an investment advisor, released the 'Mairs & Power Balanced Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The stock market reached a record high in February. However, tariff uncertainty in March led to a fall in equities, while fixed income benefited from perceived safety. The fund ended the quarter up 0.04%. The fund outperformed the benchmark composite indexes (60% S&P 500 Total Return Index and 40% Bloomberg U.S. Government/Credit Bond Index), down 1.48%, and the Morningstar Moderate Allocation peer group, which fell 0.34%. In addition, please check the fund's top five holdings to know its best picks in 2025.
In its first-quarter 2025 investor letter, Mairs & Power Balanced Fund highlighted stocks such as Bio-Techne Corporation (NASDAQ:TECH). Bio-Techne Corporation (NASDAQ:TECH), with a market capitalization of $7.544 billion, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets. The one-month return of Bio-Techne Corporation (NASDAQ:TECH) was -11.74%, and its shares lost 38.07% of their value over the last 52 weeks. On May 6, 2025, Bio-Techne Corporation (NASDAQ:TECH) stock closed at $47.72 per share.
Mairs & Power Balanced Fund stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its Q1 2025 investor letter:
"Bio-Techne Corporation (NASDAQ:TECH) underperformed due to negativity around the funding environment for biopharmaceuticals and biotech research given recent federal funding cuts and a weak venture capital funding environment. We have taken advantage of the recent weakness to add to our Bio-Techne position."
Is MKS Instruments Inc. (MKSI) the Best Scientific Instruments Stock to Buy Right Now?
A scientist working on a complex photonics instruments in a sterile laboratory setting.
Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 24 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the fourth quarter compared to 25 in the third quarter. In the second quarter of fiscal 2025, the company generated $297 million in revenues, up 9% year-over-year on both reported and organic basis. While we acknowledge the potential of Bio-Techne Corporation (NASDAQ:TECH) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
25 minutes ago
- Chicago Tribune
Wall Street futures edge lower in light trading
Wall Street futures were down marginally before the bell with earnings season winding down and much-anticipated jobs numbers landing later in the week. The Labor Department is reporting monthly job openings Tuesday. Futures for the S&P 500 fell 0.3%, as did futures for the Dow Jones Industrial Average. Nasdaq futures are off just 0.1%. Constellation Energy climbed 14% after it announced a 20-year deal with Facebook parent company Meta to provide it with nuclear power from its Illinois plant as demand for energy to run artificial intelligence rises rapidly. A month ago, Google announced a similar partnership with Elementl Power. Dollar General shares jumped 8% after it reported a far wider profit than analysts expected and record sales. After being forced to cut its outlook in a rough 2024, the bargain chain boosted its outlook for 2025 as off-price retailers shine in a weakening economy. On the global front, Beijing and Washington dialed back trade friction slightly as the U.S. extended exemptions for tariffs on some Chinese goods, including solar manufacturing equipment, that U.S. industries rely on for their own production. The U.S. Trade Representative extended those exemptions, which were due to expire on May 31, by three months through Aug. 31. The U.S. side said President Donald Trump was expecting to speak with Chinese leader Xi Jinping this week. A Chinese foreign ministry spokesperson said Tuesday that they had no information on that. Just a few weeks ago, the United States and China agreed to pause many tariff hikes that had threatened to drag the U.S. economy into a recession. Trump has been warning that U.S. businesses and households could feel some pain as he tries to use tariffs to bring more manufacturing jobs back to the country, and their on-and-off rollout has created lots of uncertainty. Markets in China advanced despite a report showing manufacturing activity slowed in May, even after China and the U.S. paused tariff hikes to allow time for talks. The survey of Chinese purchasing managers, or PMI, by the financial media group Caixin showed factory output, new export orders, purchasing activity and staffing all declined last month. Incoming new work contracted at the quickest pace in over two-and-a-half years. the report said. The situation is 'a body blow to the backbone of China's economy: small and mid-sized exporters now caught in a brutal vice grip between faltering global demand and a Washington-led tariff regime that's more carrot-and-stick diplomacy than ceasefire,' Stephen Innes of SPI Asset Management said in a commentary. However, as is often the case, investors shrugged off the bad news with the assumption that it might raise the likelihood of more market support from Beijing. Hong Kong's Hang Seng jumped 1.5% to 23,512.49, while the Shanghai Composite index rose 0.4% to 3,361.98. Tokyo's Nikkei 225 edged 0.1% lower to 37,446.81. South Korean markets were closed for a snap presidential election triggered by the ouster of Yoon Suk Yeol, a conservative who now faces an explosive trial on rebellion charges over his short-lived imposition of martial law in December. In Australia, the S&P/ASX 200 climbed 0.6% to 8,466.70. In Taiwan, the Taiex gained 0.6%, while India's Sensex lost 0.5%. In midday European trading, Germany's DAX was unchanged, while the CAC 40 in Paris shed 0.3% and Britain's FTSE 100 slipped 0.1%. U.S. benchmark crude oil was up 36 cents at $62.88 per barrel. Brent crude, the international standard, picked up 33 cents to $64.96 per barrel. The U.S. dollar rose to 143.10 Japanese yen from 142.71 yen. The euro slipped to $1.1391 from $1.1443.
Yahoo
30 minutes ago
- Yahoo
Evaxion receives grant funding to design new polio vaccine
Evaxion awarded a grant from the Gates Foundation Grant funds research aimed at ultimately eradicating polio, a highly infectious viral disease Evaxion will apply its leading AI-Immunology™ platform to identify and combine various antigens to combat the virus and develop design options for a potential new vaccine construct Risk of a global polio resurgence and health crisis remain, thus a new vaccine concept is warranted COPENHAGEN, Denmark, June 3, 2025 - Evaxion A/S (NASDAQ: EVAX) ('Evaxion'), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives funding support from the Gates Foundation to help the world eradicate polio (poliomyelitis) by exploring design options for a new and unique vaccine. Despite polio vaccines being available for decades, the highly infectious viral disease is yet to be completely eradicated, meaning that the risk of a global polio resurgence and health crisis remain. Thus, a new vaccine concept could increase the possibility of eradicating the virus once and for all. The project will combine Evaxion's leading and clinically validated AI-Immunology™ platform with support from the Gates Foundation. Evaxion will deploy AI-Immunology™ to identify and combine various antigens to combat the virus. Based on these findings, a number of new antigen constructs will be designed for selection and validation. The work will be supported by the grant from the Gates Foundation, meaning there will be no financial cost for Evaxion. 'We are thrilled to receive support from the Gates Foundation and help the world achieve the goal of completely eradicating polio. We are excited to apply our AI-Immunology™ platform to combat yet another infectious disease. The grant allows for further application and validation of our platform without adding to our operational spend,' says Christian Kanstrup, CEO of Evaxion. Groundbreaking new approachCurrent polio vaccines are based on inactivated or attenuated versions of the virus. This creates significant issues in certain settings and leaves an unmet need in the context of the polio endgame for a new and better vaccine not based on the virus itself. New vaccine constructs eliminating the use of live viruses in vaccine production would be a great advantage, removing the potential safety risks of growing and working with the virus. Such a groundbreaking new vaccine approach is what the project aims at creating, bringing forward an effective and safer alternative to current polio vaccines. About polioPolio (poliomyelitis) mainly affects children under five years of age. One in 200 infections leads to irreversible paralysis for type 1 wild poliovirus. Among those paralyzed, 5–10% die when their breathing muscles become immobilized. Cases due to wild poliovirus have decreased by over 99% since 1988, from an estimated 350,000 cases in more than 125 endemic countries, to two endemic countries. As long as a single child remains infected, children in all countries are at risk of contracting polio. Failure to eradicate polio from these last remaining strongholds could result in a global resurgence of the disease. Source: The World Health Organization. Contact information Evaxion A/SMads KronborgVice President, Investor Relations & Communication+45 53 54 82 96 mak@ About Evaxion Evaxion is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients' lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website. Forward-looking statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words 'target,' 'believe,' 'expect,' 'hope,' 'aim,' 'intend,' 'may,' 'might,' 'anticipate,' 'contemplate,' 'continue,' 'estimate,' 'plan,' 'potential,' 'predict,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could,' and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at We do not assume any obligation to update any forward-looking statements except as required by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Pinterest Stock Gains on JPMorgan Rating Upgrade, Price Target Raise
Pinterest shares rose in premarket trading Tuesday after JPMorgan analysts upgraded their rating and lifted their price target on the social media stock. The analysts lifted the stock to "overweight" from "neutral," and bumped their price target to $40 from $35. The analysts said Pinterest is improving its user numbers and ad technology, both of which should help drive (PINS) shares rose in premarket trading Tuesday after JPMorgan analysts upgraded their rating and lifted their price target on the social media stock. The analysts lifted the stock to "Overweight" from "Neutral," and bumped their price target to $40 from $35. That brings JPMorgan in line with most other analysts covering the stock who are tracked by Visible Alpha, as 16 call it a "Buy" and just four a "Hold," with an average price target of $39.75. They noted that while Pinterest shares are up since the start of the year, they are still about 18% below their February highs while the S&P 500 has recovered to just about 3% below its February record level that month. Pinterest is "leveraging its full funnel ad approach and automation/AI capabilities—including Performance+—to capture a greater share of ad spending" from advertisers with $1 billion to $30 billion in annual revenue, the analysts wrote. Some larger advertisers are already spending 5% to 10% of their advertising budget on the platform, they added. The social media platform is growing its monthly active users (MAU) base, with 85% coming directly to Pinterest through its mobile app, the analysts said. They cited that number as a key reason for their upgrade, as Pinterest generates roughly 90% of its revenue through its app, "which limits PINS' exposure to Google & broader overall search disruption," they wrote. Pinterest shares, which entered the day up 10% this year, rose 4% less than an hour before the opening bell. Read the original article on Investopedia
